文献速递眼底病与葡萄膜炎神经眼科

阿尔茨海默病乙酰胆碱酯酶抑制剂治疗与年龄相关性黄斑变性发病

Alzheimer Disease Treatment With Acetylcholinesterase Inhibitors and Incident Age-Related Macular Degeneration.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

这项在美国退伍军人健康管理局医疗系统开展的倾向评分匹配回顾性队列研究纳入21823例55至80岁、基线无年龄相关性黄斑变性的阿尔茨海默病患者,评估乙酰胆碱酯酶抑制剂用药与年龄相关性黄斑变性首发诊断的关联。倾向评分匹配Cox模型显示,乙酰胆碱酯酶抑制剂治疗每增加一年,年龄相关性黄斑变性风险降低6%(HR 0.94,95%CI 0.89-0.99)。作者指出该观察性研究仅报告小幅风险降低,因果关系需随机临床试验确定,并需在不同人群中进一步验证。

要点

  • 21823例阿尔茨海默病退伍军人中,乙酰胆碱酯酶抑制剂治疗每增加一年与年龄相关性黄斑变性风险降低6%相关(HR 0.94,95%CI 0.89-0.99)。
  • 该关联来自倾向评分匹配的回顾性队列分析,作者认为因果关系需随机临床试验确定。
  • 作者指出需在不同人群中进一步研究以验证上述发现。

核心结论

  • 这项观察性研究报告,接受乙酰胆碱酯酶抑制剂的阿尔茨海默病退伍军人中年龄相关性黄斑变性风险小幅降低。
  • 作者指出,确定因果关系需要随机临床试验,并需进一步研究在不同人群中验证这些发现。

研究设计与样本

  • 研究为倾向评分匹配的回顾性队列研究,地点为美国退伍军人健康管理局医疗系统内的卫生保健机构,时间范围为2000年1月至2023年9月。
  • 纳入标准为退伍军人数据库中55至80岁确诊阿尔茨海默病且既往无年龄相关性黄斑变性诊断的患者,暴露为配发用于阿尔茨海默病药物治疗的乙酰胆碱酯酶抑制剂,主要结局为首次诊断年龄相关性黄斑变性。
  • 共纳入21823例阿尔茨海默病退伍军人,平均(标准差)年龄72.3(6.1)岁,男性21313例(97.7%),女性510例(2.3%)。

主要发现

  • 倾向评分匹配Cox模型显示,乙酰胆碱酯酶抑制剂治疗每增加一年与年龄相关性黄斑变性风险降低6%相关(HR 0.94,95%CI 0.89-0.99)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出,确定因果关系需要随机临床试验。
  • 原文指出,需进一步研究在不同人群中验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Age-related macular degeneration (AMD) is a serious and common ophthalmologic disorder that is hypothesized to result, in part, from inflammatory reactions in the macula. Alzheimer disease (AD) treatment, acetylcholinesterase inhibitors (AChEIs), have anti-inflammatory effects and it remains unclear if they modify the risk of AMD. OBJECTIVE: To investigate the association between AChEI medications and the incidence of AMD. DESIGN, SETTING, AND PARTICIPANTS: This propensity score-matched retrospective cohort study took place at health care facilities within the US Department of Veterans Affairs (VA) health care system from January 2000 through September 2023. Participants included patients diagnosed with AD between ages 55 and 80 years with no preexisting diagnosis of AMD in the VA database. EXPOSURE: AChEIs prescription dispensed as pharmacologic treatments for AD. MAIN OUTCOMES AND MEASURE: The first diagnosis of AMD. RESULTS: A total of 21 823 veterans with AD (mean [SD] age, 72.3 [6.1] years; 21 313 male participants [97.7%] and 510 female participants [2.3%]) were included. Propensity score-matched Cox model reveals each additional year of AChEI treatment was associated with a 6% lower hazard of AMD (hazard ratio, 0.94; 95% CI, (0.89-0.99). CONCLUSIONS AND RELEVANCE: This observational study reports a small reduction in the risk of AMD among veterans with AD receiving AChEIs. Randomized clinical trials would be needed to determine if there is a cause-and-effect relationship and further research is required to validate these findings across diverse populations.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sutton SS, Magagnoli J, Cummings TH, et al. Alzheimer Disease Treatment With Acetylcholinesterase Inhibitors and Incident Age-Related Macular Degeneration. JAMA Ophthalmol. 2024. PMID: 38175625. doi:10.1001/jamaophthalmol.2023.6014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。